Avtor/Urednik		Ugovšek, Sabina; Zupan, Janja; Rehberger Likozar, Andreja; Šebeštjen, Miran
Naslov		Influence of lipid-lowering drugs on inflammation: what is yet to be done?
Tip		članek
Vol. in št.		Letnik 18, št. 4
Leto izdaje		2021
Obseg		str. 855-869
ISSN		1896-9151 - Archives of medical science : AMS
Jezik		eng
Abstrakt		Atherosclerosis is a chronic inflammatory disease that is associated with risk of cardiovascular events. The best-characterised and well-standardised clinical indicator of inflammation is C-reactive protein. Current evidence-based drug therapies for prevention and treatment of cardiovascular diseases are mainly focused on reduction of low-density lipoprotein cholesterol. However, these drugs do not provide sufficient protection against recurrent cardiovascular events. One of the possible mechanisms behind this recurrence might be the persistence of residual inflammation. For the most commonly used lipid-lowering drugs, the statins, their reduction of cardiovascular events goes beyond lowering of low-density lipoprotein cholesterol. Here, we review the effects of these lipid-lowering drugs on inflammation, in terms of statins, ezetimibe, fibrates, niacin, proprotein convertase subtilisin/kexin type 9 inhibitors, bempedoic acid, ethyl eicosapentaenoic acid and antisense oligonucleotides. We focus in particular on C-reactive protein, and discuss how the effects of the statins might be related to reduced rates of cardiovascular events.
Deskriptorji		Kardiovaskularni sistem Atersokleroza Vnetje Lipidi
Proste vsebinske oznake		C-reactive protein inflammation atherosclerosis lipid-lowering drugs